ArticleAmerican journal of preventive medicine2026
Characterization of Women's Health Benefit Claims Made on Cannabis E-Commerce Platforms: A Retrospective Market Surveillance Study.
Article in American journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionConsumer interest in cannabis-derived products remains high, including among women, a growing demographic group. This study examined women's reproductive health claims in cannabis-derived product e-commerce listings to better understand their potential consumer risk.
methodsThis study involved 3 phases: (1) data mining U.S. product listings from cannabis e-commerce websites Leafly and Weedmaps; (2) keyword filtering related to women's health and reproductive topics; and (3) content coding of cannabis-derived product listings for women's health benefits, including product characteristics, such as route of administration, and any accompanying health warnings and user-generated reviews all conducted in September-November 2023.
resultsA total of 1,463,510 unique cannabis-derived product listings were collected from Leafly and Weedmaps. After keyword filtering and content coding, 408 listings mapped to 465 health benefit claims across 5 major women's health areas: menstrual cycle (57.2%, n=266), fertility (14.0%, n=65), women's health conditions (13.1%, n=61), menopausal transition (15.0%, n=70), and maternal health (0.7%, n=3). Among these 408 cannabis-derived product listings, only 6.6% (n=27) contained disclaimers with health warning language. For products making women's health claims, the top product route of administration was topical/transdermal application (e.g., dermatological agents, transdermal products, n=135). Product reviews contained 14 comments with thematic relevance to stated health benefit claim(s), including with 12 (85.7%) positive and 2 (14.3%) negative.
conclusionsThis study found >400 unique cannabis-derived products promoting various women-focused health benefits on 2 cannabis e-commerce sites, despite known reproductive and maternal health risks. Additional research is needed to understand how women perceive these marketed benefits and how they influence product use and behavior.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.